<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954628</url>
  </required_header>
  <id_info>
    <org_study_id>AQX-1125-202</org_study_id>
    <nct_id>NCT01954628</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AQX-1125 in Unstable COPD</brief_title>
  <acronym>FLAGSHIP</acronym>
  <official_title>The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquinox Pharmaceuticals (Canada) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquinox Pharmaceuticals (Canada) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of 12 weeks of treatment with
      once daily administration of AQX-1125 compared to placebo in subjects following exacerbations
      of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology
      2-containing Inositol-5'-Phosphatase 1) pathway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality
      worldwide. Acute exacerbations of COPD are usually treated with steroids and/or antibiotics.
      Currently this conventional therapy has significant side effects including osteoporosis,
      cataracts and suppression of the immune system (from the steroids) and increasing bacterial
      resistance and other side effects from the use of antibiotics. During an acute exacerbation
      of COPD, the inflammation in the airways increases.

      AQX-1125 represents a new type drug that based current data is thought decrease the
      inflammatory process and therefore may provide a therapeutic benefit in the treatment of
      COPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary variable (endpoint) of this study is the difference in the Area Above the Curve (AAC) for the daily EXACT score from baseline to Week 12 between subjects treated with AQX-1125 and placebo.The EXACT questionnaire is a patient reported outcome (PRO) measure designed to standardise the method for evaluating the frequency, severity and duration of acute exacerbations of COPD. The EXACT is a 14-item daily questionnaire where each item is assessed on a 5 or 6 point ordinal scale. Participants completed the EXACT questionnaire on a daily basis via an electronic diary from Day 1 (pre-dose) to Day 84 (week 12). Higher scores on the daily EXACT questionnaire indicate a more severe health state. When the post-treatment EXACT scores are lower (i.e. improved symptoms) than baseline EXACT, the AACs are positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Assessment Tool (CAT) Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the COPD Assessment Tool (CAT) score.The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from baseline indicates improvement. The change in total CAT score from Day 1, before taking study drug (baseline), to end of the 12 week treatment period was compared between the two treatments using an ANOVA model adjusting for treatment and region and including the baseline score as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the Number of COPD Exacerbations (Medically Treated Event (MTE))</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the number of COPD exacerbations (MTE).
COPD exacerbations were referred to as Medically Treated Exacerbations (MTEs) and identified as a change in symptoms and/or signs of COPD requiring prescription of one or both of: (1) Course of oral corticosteroids or (2) Antibiotic(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the time to first exacerbation requiring medical intervention of oral corticosteroids and/or antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects With at Least One COPD Exacerbation.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of subjects that presented with a COPD exacerbation during the 12 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on forced expiratory volume in 1 second [FEV1].
FEV1 was determined from post-bronchodilator spirometry testing done at clinic visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AQX-1125 Concentrations in Plasma (Trough Values)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary objectives are to evaluate the pharmacokinetics (PK) of AQX-1125 in plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>AQX-1125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x AQX-1125 capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 x Placebo capsule daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQX-1125</intervention_name>
    <description>Synthetic SHIP1 activator</description>
    <arm_group_label>AQX-1125</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged â‰¥40 years at screening

          2. History of COPD for at least 18 months prior to screening, characterised by excessive
             sputum production

          3. Chronic productive cough for at least 3 months in each of the 2 years prior to
             screening (if other causes of productive cough have been excluded) and/or an
             exacerbation of COPD with predominantly bronchitic symptoms at enrolment

          4. At least 2 documented exacerbations during the last 18 months prior to screening.

          5. Presentation of a diagnosed acute exacerbation of COPD, or have recently (within 3
             days) been discharged from hospital due to an acute exacerbation of COPD

          6. Ability to perform pulmonary function testing and with documented fixed airway
             obstruction determined by an FEV1 /FVC [forced vital capacity] ratio
             (post-bronchodilator) of &lt;0.70 and a predicted FEV1 value of 30%-80% of normal within
             the 6 months prior to Visit 1.

          7. Former smoker or current smoker, both with a smoking history of at least 10 pack years

        Exclusion Criteria:

          1. Diagnosis of other relevant lung disease (e.g. asthma, cystic fibrosis [CF] or
             significant non-CF bronchiectasis)

          2. Known alpha-1-antitrypsin deficiency

          3. Treatment with roflumilast or theophylline within 1 month prior to screening

          4. Lobar pneumonia, with current positive chest X-ray (CXR) or within the 3 months prior
             to screening including the presence of any new radiological infiltrate on CXR within
             the previous two weeks

          5. Hospitalisation for more than 7 days for current acute exacerbation, or the
             requirement for intubation during hospitalisation

          6. For outpatients, prior medical history indicating that previous exacerbations required
             &gt;3 weeks to stabilise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen B Shrewsbury, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aquinox Pharmaceuticals (Canada) Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory &amp; Sleep Medicine, Westmead Hospital</name>
      <address>
        <city>Wentworthville</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedicum Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CsongrÃ¡d Megyei Melkasi BetegsÃ©gek SzakkÃ³rhÃ¡za</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung and Allergy Clinic, SkÃ¥ne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/</url>
    <description>GOLD COPD Guidelines</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <results_first_submitted>May 8, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2017</results_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exacerbation of COPD</keyword>
  <keyword>Unstable COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 8 countries: Australia, Denmark, Finland, Hungary, New Zealand, Poland, Sweden and US. US subjects participating in 6 month safety follow-up continued in the study until November 2015.</recruitment_details>
      <pre_assignment_details>Four hundred subjects were randomized into two subsets: (1) Subjects suitable for outpatient treatment of a current exacerbation of COPD (within 3 days of diagnosis) &amp; (2) Subjects who had been hospitalized in order to treat their exacerbation for not more than 7 days &amp; were ready to be discharged or had been discharged within the last 3 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AQX-1125 (200 mg)</title>
          <description>AQX-1125 (200 mg capsule), oral once daily for 12 weeks. All standard of care treatments for COPD were permitted throughout the study with the exception of Roflumilast and Theophylline.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (matching AQX-1125 capsule), oral, once daily for 12 weeks. Placebo control. All standard of care treatments for COPD were permitted throughout the study with the exception of Roflumilast and Theophylline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Population</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>US 6 Month Ophthalmology Safety Visit</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety set.</population>
      <group_list>
        <group group_id="B1">
          <title>AQX-1125 (200 mg)</title>
          <description>1 x AQX-1125 capsule daily
AQX-1125: Synthetic SHIP1 activator</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 x Placebo capsule daily
Placebo: Placebo control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="8.2"/>
                    <measurement group_id="B2" value="64.4" spread="8.5"/>
                    <measurement group_id="B3" value="65.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="386"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="6.6"/>
                    <measurement group_id="B2" value="27.2" spread="6.1"/>
                    <measurement group_id="B3" value="27.6" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of COPD Exacerbations in Last 18 months</title>
          <units>number of exacerbations/18 months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="1.7"/>
                    <measurement group_id="B2" value="3.0" spread="1.4"/>
                    <measurement group_id="B3" value="3.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Hospitalizations for COPD</title>
          <units>number of previous hospitlizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="3.0"/>
                    <measurement group_id="B2" value="0.9" spread="1.6"/>
                    <measurement group_id="B3" value="1.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years Since COPD Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="5.7"/>
                    <measurement group_id="B2" value="7.8" spread="5.9"/>
                    <measurement group_id="B3" value="8.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current Smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Pack Years</title>
          <units>pYears</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="22.0"/>
                    <measurement group_id="B2" value="41.2" spread="20.9"/>
                    <measurement group_id="B3" value="40.7" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nicotine Replacement Therapy Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-bronchodilator FEV1/FVC Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.51" spread="0.11"/>
                    <measurement group_id="B2" value="0.52" spread="0.11"/>
                    <measurement group_id="B3" value="0.52" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-bronchodilator FEV1% of Predicted</title>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="13.9"/>
                    <measurement group_id="B2" value="50.9" spread="13.2"/>
                    <measurement group_id="B3" value="50.6" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period.</title>
        <description>The primary variable (endpoint) of this study is the difference in the Area Above the Curve (AAC) for the daily EXACT score from baseline to Week 12 between subjects treated with AQX-1125 and placebo.The EXACT questionnaire is a patient reported outcome (PRO) measure designed to standardise the method for evaluating the frequency, severity and duration of acute exacerbations of COPD. The EXACT is a 14-item daily questionnaire where each item is assessed on a 5 or 6 point ordinal scale. Participants completed the EXACT questionnaire on a daily basis via an electronic diary from Day 1 (pre-dose) to Day 84 (week 12). Higher scores on the daily EXACT questionnaire indicate a more severe health state. When the post-treatment EXACT scores are lower (i.e. improved symptoms) than baseline EXACT, the AACs are positive.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS). The FAS was all randomized subjects who have received at least one dose of the study drug and had at least one efficacy assessment (valid diary entries) post-baseline. Imputation, the mean of the last 5 days, counted backwards from day of last recording, in the treatment period will be used.</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 (200mg)</title>
            <description>1 x AQX-1125 capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 x Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period.</title>
          <description>The primary variable (endpoint) of this study is the difference in the Area Above the Curve (AAC) for the daily EXACT score from baseline to Week 12 between subjects treated with AQX-1125 and placebo.The EXACT questionnaire is a patient reported outcome (PRO) measure designed to standardise the method for evaluating the frequency, severity and duration of acute exacerbations of COPD. The EXACT is a 14-item daily questionnaire where each item is assessed on a 5 or 6 point ordinal scale. Participants completed the EXACT questionnaire on a daily basis via an electronic diary from Day 1 (pre-dose) to Day 84 (week 12). Higher scores on the daily EXACT questionnaire indicate a more severe health state. When the post-treatment EXACT scores are lower (i.e. improved symptoms) than baseline EXACT, the AACs are positive.</description>
          <population>Full Analysis Set (FAS). The FAS was all randomized subjects who have received at least one dose of the study drug and had at least one efficacy assessment (valid diary entries) post-baseline. Imputation, the mean of the last 5 days, counted backwards from day of last recording, in the treatment period will be used.</population>
          <units>Area Above Curve on Daily Exact Score</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.4" lower_limit="290.7" upper_limit="540.1"/>
                    <measurement group_id="O2" value="391.7" lower_limit="268.2" upper_limit="515.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size based on area above the daily EXACT score curve (AAC) from Day 1 to Day 29 from subjects with an acute COPD exacerbation, collected over 28 days. Assuming a residual SD of 500 points, a sample size of 200 subjects per arm would be expected to have an 80% power to detect a true treatment difference in the AAC of 140 points over 12-weeks treatment, using a 2-sided test; alpha-level of 0.05.This difference corresponds to a mean daily improvement of 1.67 points on the EXACT symptom score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.759</p_value>
            <p_value_desc>AAC were compared between treatments using an analysis of variance model adjusting for treatment and region as factors and including the baseline score as a covariate.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least sqaure mean difference</param_type>
            <param_value>23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-128.3</ci_lower_limit>
            <ci_upper_limit>175.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Assessment Tool (CAT) Score</title>
        <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the COPD Assessment Tool (CAT) score.The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from baseline indicates improvement. The change in total CAT score from Day 1, before taking study drug (baseline), to end of the 12 week treatment period was compared between the two treatments using an ANOVA model adjusting for treatment and region and including the baseline score as a covariate.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set. Missing post-treatment data imputed using the last observation carried forward principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 (200 mg)</title>
            <description>1 x AQX-1125 capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 x Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Assessment Tool (CAT) Score</title>
          <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the COPD Assessment Tool (CAT) score.The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from baseline indicates improvement. The change in total CAT score from Day 1, before taking study drug (baseline), to end of the 12 week treatment period was compared between the two treatments using an ANOVA model adjusting for treatment and region and including the baseline score as a covariate.</description>
          <population>Full analysis set. Missing post-treatment data imputed using the last observation carried forward principle.</population>
          <units>COPD Assessment Tool Score</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.05" lower_limit="-5.06" upper_limit="-3.04"/>
                    <measurement group_id="O2" value="-3.71" lower_limit="-4.71" upper_limit="-2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANOVA model with fixed factors treatment, region and baseline total CAT score as covariate were used. Missing post-treatment data were imputed using the Last Observation Carried Forward principle.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>ANOVA</method>
            <param_type>Least sqaure mean difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.57</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of the Number of COPD Exacerbations (Medically Treated Event (MTE))</title>
        <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the number of COPD exacerbations (MTE).
COPD exacerbations were referred to as Medically Treated Exacerbations (MTEs) and identified as a change in symptoms and/or signs of COPD requiring prescription of one or both of: (1) Course of oral corticosteroids or (2) Antibiotic(s).</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set was used and analyzed using the negative binomial regression model with fixed factors treatment, region and time in study as offset. Adjusted means for treatment group shows number of exacerbations/year.</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 (200 mg)</title>
            <description>1 x AQX-1125 capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 x Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of the Number of COPD Exacerbations (Medically Treated Event (MTE))</title>
          <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the number of COPD exacerbations (MTE).
COPD exacerbations were referred to as Medically Treated Exacerbations (MTEs) and identified as a change in symptoms and/or signs of COPD requiring prescription of one or both of: (1) Course of oral corticosteroids or (2) Antibiotic(s).</description>
          <population>Full analysis set was used and analyzed using the negative binomial regression model with fixed factors treatment, region and time in study as offset. Adjusted means for treatment group shows number of exacerbations/year.</population>
          <units>Number of exacerbations/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.776" lower_limit="1.374" upper_limit="2.297"/>
                    <measurement group_id="O2" value="1.641" lower_limit="1.261" upper_limit="2.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The number of subjects with at least one COPD exacerbation were summarised by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.646</p_value>
            <method>Negative binomial regression model</method>
            <method_desc>Negative binomial regression model with fixed factors treatment, region and time in study as offset.</method_desc>
            <param_type>Least sqaure mean difference</param_type>
            <param_value>1.083</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.771</ci_lower_limit>
            <ci_upper_limit>1.520</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation</title>
        <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the time to first exacerbation requiring medical intervention of oral corticosteroids and/or antibiotics.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 (200 mg)</title>
            <description>1 x AQX-1125 capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 x Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation</title>
          <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the time to first exacerbation requiring medical intervention of oral corticosteroids and/or antibiotics.</description>
          <population>Full analysis set</population>
          <units>day(s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="21.3"/>
                    <measurement group_id="O2" value="43.9" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects With at Least One COPD Exacerbation.</title>
        <description>The number of subjects that presented with a COPD exacerbation during the 12 week treatment period.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 (200 mg)</title>
            <description>1 x AQX-1125 capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 x Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With at Least One COPD Exacerbation.</title>
          <description>The number of subjects that presented with a COPD exacerbation during the 12 week treatment period.</description>
          <population>Full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1</title>
        <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on forced expiratory volume in 1 second [FEV1].
FEV1 was determined from post-bronchodilator spirometry testing done at clinic visits.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set. Missing post-treatment data imputed using the last observation carried forward principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 (200mg)</title>
            <description>1 x AQX-1125 capsule daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 x Placebo capsule daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1</title>
          <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on forced expiratory volume in 1 second [FEV1].
FEV1 was determined from post-bronchodilator spirometry testing done at clinic visits.</description>
          <population>Full analysis set. Missing post-treatment data imputed using the last observation carried forward principle.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.06" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.03" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing post-treatment data was imputed using the Last Observation Carried Forward principle.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AQX-1125 Concentrations in Plasma (Trough Values)</title>
        <description>The secondary objectives are to evaluate the pharmacokinetics (PK) of AQX-1125 in plasma.</description>
        <time_frame>12 weeks</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125 Week 2</title>
            <description>AQX-1125 Week 2 PK</description>
          </group>
          <group group_id="O2">
            <title>AQX-1125 Week 4</title>
            <description>AQX-1125 Week 4 PK</description>
          </group>
          <group group_id="O3">
            <title>AQX-1125 Week 12</title>
            <description>Week 12 PK Week 12 PK</description>
          </group>
        </group_list>
        <measure>
          <title>AQX-1125 Concentrations in Plasma (Trough Values)</title>
          <description>The secondary objectives are to evaluate the pharmacokinetics (PK) of AQX-1125 in plasma.</description>
          <population>PK Population</population>
          <units>micrograms per Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.1" spread="70.5"/>
                    <measurement group_id="O2" value="163.9" spread="74.5"/>
                    <measurement group_id="O3" value="120.5" spread="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks treatment; up to 6 months safety follow-up.</time_frame>
      <desc>SAEs listed occurred in &gt;1 subjects per treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>AQX-1125</title>
          <description>1 x AQX-1125 capsule daily
AQX-1125: Synthetic SHIP1 activator</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 x Placebo capsule daily
Placebo: Placebo control</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <description>COPD exacerbations occurring during the study should not have been reported as SAEs (as per protocol). However, 10 events were reported (1 in AQX-1125 group and 9 in placebo).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators shall not publish any articles or make any presentations or communications (including any written, oral or electronic manuscript, abstract, presentation or other publication) relating to the Services, Sponsor Information, Study Drug or other Material, Deliverables or other Developments, in whole or part, without the prior written consent of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Secondary objective of &quot;The frequency and severity of AEs and changes in physical exam, vital signs, ophthalmic exam, laboratory tests, weight, ECG, and con meds&quot; was monitored throughout the study, clinically significant events were reported as AEs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical</name_or_title>
      <organization>Aquinox Pharmaceuticals (Canada) Inc.</organization>
      <phone>+1 (604) 629-9223</phone>
      <email>clinical@aqxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

